Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mother Dirt is a biotechnology-driven skincare company that specializes in microbiome-based products designed to restore the skin's natural balance. The company is best known for its use of live Ammonia-Oxidizing Bacteria (AOB), specifically Nitrosomonas eutropha, which was once a common component of the human skin microbiome before being stripped away by modern hygiene. Its flagship product, the AO+ Mist, is a live probiotic spray that helps improve skin clarity, texture, and resilience by converting ammonia in sweat into beneficial byproducts like nitrite and nitric oxide. Originally developed as the consumer arm of the clinical-stage biotech firm AOBiome, Mother Dirt has successfully bridged the gap between advanced microbial research and commercial personal care. In early 2024, the brand was acquired by Galderma, a global leader in dermatology, to enhance its science-based sensitive skincare portfolio. The company continues to focus on biome-friendly formulations that support a healthy and diverse skin ecosystem.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mother Dirt.